Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022
September 07, 2022 07:00 ET
|
Amryt Pharma plc
Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 DUBLIN, Ireland, and Boston MA, September 7, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage...
Amryt Reports Record Q2 2022 Results
August 04, 2022 07:00 ET
|
Amryt Pharma plc
Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin...
Amryt to Report Q2 2022 Results on August 4, 2022
July 21, 2022 07:00 ET
|
Amryt Pharma plc
DUBLIN, Ireland, and Boston MA, July 21, 2022, Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for...
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome
July 14, 2022 07:00 ET
|
Amryt Pharma plc
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland, and Boston MA, July 14, 2022, Amryt (Nasdaq: AMYT), a...
Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022
July 07, 2022 07:00 ET
|
Amryt Pharma plc
Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022 - Key highlights include efficacy of Oleogel-S10 (birch triterpenes) on accelerated wound healing, data on...
Results of Annual General Meeting
July 01, 2022 07:00 ET
|
Amryt Pharma plc
DUBLIN, Ireland, and Boston MA, July 1, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare...
Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer
June 27, 2022 07:00 ET
|
Amryt Pharma plc
Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company...
Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA
June 24, 2022 07:00 ET
|
Amryt Pharma plc
Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA Filsuvez® recently approved by the European Commission for the treatment of EB DUBLIN, Ireland, and Boston MA, June 24,...
European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB
June 23, 2022 07:00 ET
|
Amryt Pharma plc
European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB Filsuvez® will be the first and only approved treatment for EB Patients DUBLIN, Ireland, and Boston MA,...
Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022
June 13, 2022 08:00 ET
|
Amryt Pharma plc
Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022 Data from the MPOWERED OLE and first presentation of open-label extension (OLE) data from 2nd...